INTERNATIONAL JOURNAL OF PHARMACEUTICS

投稿咨询

官方网站：http://www.elsevier.com/wps/find/journaldescription.cws_home/505513/description

投稿网址：http://ees.elsevier.com/ijp/

PMC链接：http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0378-5173%5BISSN%5D

《国际药学杂志》提供了一种出版创新论文、评论、小型评论、简短交流和笔记的媒介，涉及物理、化学、生物、微生物和工程研究，涉及药物在体内和体外传递系统的概念、设计、生产、特性和评价。“药物”定义为任何治疗或诊断实体，包括寡核苷酸、基因构建物和放射性药物。特别感兴趣的领域包括:物理药学;高分子化学和物理化学在制药中的应用赋形剂的功能和特性;生物药剂学;吸收机制;膜的功能和运输;新颖的送货路线和方式;反应性传递系统、反馈和控制机制，包括生物传感器;细胞和分子生物学在药物传递中的应用前药设计;辅料(carrier-ligand互动);生物技术(蛋白质和肽传递)。编辑政策出版的首要标准是原创性、高科学质量和对多学科读者的兴趣。未经实验细节充分证实的论文将不予发表。任何技术问题都将提交给作者，尽管编辑保留在不改变技术内容的情况下修改文本的权利。以多重作者身份提交的稿件将在假定所有列出的作者都同意提交的情况下进行审查，并且最终稿件的副本已得到所有作者的批准，并已由进行工作的实验室的主管当局默认或明确地批准。未经编辑出版者同意，稿件不得在其他地方以相同的形式、相同的文字或者其他文字发表。在提交论文发表时，作者必须在附信中说明他们的工作或研究方法所体现的新颖性。常规的生物等效性研究不太可能受到青睐。本署将不会发表任何论文，不完全披露所使用的配方的性质或对产品、药物或辅料的性能至关重要的材料的详情。结果可预测的工作，例如在环糊精中加入另一种药物以产生更强的溶解性，将不会发表，除非它对基本原理提供了新的见解。

The International Journal of Pharmaceutics provides a medium for the publication of innovative papers, reviews, mini-reviews, short communications and notes dealing with physical, chemical, biological, microbiological and engineering studies related to the conception, design, production, characterisation and evaluation of drug delivery systems in vitro and in vivo. "Drug" is defined as any therapeutic or diagnostic entity, including oligonucleotides, gene constructs and radiopharmaceuticals. Areas of particular interest include: physical pharmacy; polymer chemistry and physical chemistry as applied to pharmaceutics; excipient function and characterisation; biopharmaceutics; absorption mechanisms; membrane function and transport; novel routes and modes of delivery; responsive delivery systems, feedback and control mechanisms including biosensors; applications of cell and molecular biology to drug delivery; prodrug design; bioadhesion (carrier-ligand interactions); and biotechnology (protein and peptide delivery). Editorial Policy The over-riding criteria for publication are originality, high scientific quality and interest to a multidisciplinary audience. Papers not sufficiently substantiated by experimental detail will not be published. Any technical queries will be referred back to the author, although the Editors reserve the right to make alterations in the text without altering the technical content. Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur with the submission and that a copy of the final manuscript has been approved by all authors and tacitly or explicitly by the responsible authorities in the laboratories where the work was carried out. If accepted, the manuscript shall not be published elsewhere in the same form, in either the same or another language, without the consent of the Editors and Publisher. Authors must state in a covering letter when submitting papers for publication the novelty embodied in their work or in the approach taken in their research. Routine bioequivalence studies are unlikely to find favour. No paper will be published which does not disclose fully the nature of the formulation used or details of materials which are key to the performance of a product, drug or excipient. Work which is predictable in outcome, for example the inclusion of another drug in a cyclodextrin to yield enhanced dissolution, will not be published unless it provides new insight into fundamental principles.